Impact of Low Molecular Weight Heparin on Overall Survival in Patients with Advanced Lung Cancer: A Retrospective Study
American Journal of Clinical and Experimental Medicine
Volume 5, Issue 5, September 2017, Pages: 173-175
Received: Jul. 20, 2017;
Accepted: Aug. 14, 2017;
Published: Sep. 4, 2017
Views 1911 Downloads 85
Rammey Hassan, Department of Oncology, University of Cincinnati Medical Center, Cincinnati, USA
Shuchi Gulati, Department of Oncology, University of Cincinnati Medical Center, Cincinnati, USA
Yellu Mahender, Department of Oncology, University of Cincinnati Medical Center, Cincinnati, USA
Ihab Eldessouki, Department of Oncology, University of Cincinnati Medical Center, Cincinnati, USA
Nabeela Iffat Siddiqi, Department of Oncology, University of Cincinnati Medical Center, Cincinnati, USA
Changchun Xie, Division of Biostatistics and Bioinformatics, University of Cincinnati, Cincinnati, USA
Jane Pruemer, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, USA
Nagla Abdel Karim, Department of Oncology, University of Cincinnati Medical Center, Cincinnati, USA
Follow on us
Low Molecular Weight Heparin (LMWH) is approved for treatment of and secondary prophylaxis against thromboembolic events in patients with cancer. However, its role in improving Overall Survival (OS) remains unclear. A retrospective study to evaluate effect of LMWH on OS in advanced lung cancer was conducted by retrospectively identifying patients with advanced lung cancer (stage IIIA, IIIB and IV) including non-small cell, small cell and rare histopathologic subtypes from 2004 to 2014. Patients with early stage lung cancer and those with incomplete information were excluded. Data on patient demographics (age, gender, ethnicity), histopathology, staging, medications (including chemotherapy and anticoagulants) and patient outcome were collected. Death was considered as the final endpoint. Patients with and without LMWH use were identified. This study did not find an improvement in OS with use of LMWH in advanced stage lung cancer patients. Even though the results were not statistically significant, there was a trend towards higher mortality in patients treated with LMWH for thrombosis compared to patients without thrombosis. Future prospective studies using a larger patient population should evaluate the impact of prophylactic versus therapeutic LMWH on OS in advanced lung cancer.
Lung Cancer, Low Molecular Weight Heparin, Venous Thromboembolism, Thrombosis
To cite this article
Nabeela Iffat Siddiqi,
Nagla Abdel Karim,
Impact of Low Molecular Weight Heparin on Overall Survival in Patients with Advanced Lung Cancer: A Retrospective Study, American Journal of Clinical and Experimental Medicine.
Vol. 5, No. 5,
2017, pp. 173-175.
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1): 7-30. doi: 10.3322/caac.21332.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87-108. doi: 10.3322/caac.21262 [doi].
Bréchot JM. Thrombosis and Lung Cancer, 2005; 22(6 Pt 2): 8S33-7. PMID: 16340833
Maraveyas A, Johnson M. Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Br J Cancer. 2009; 100(12): 1837-1841. doi: 10.1038/sj.bjc.6605091.
Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med. 2007; 13(5): 362-367. doi: 10.1097/MCP.0b013e328209413c.
Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol). 1999; 11(2): 105-110. http://www.ncbi.nlm.nih.gov/pubmed/10378636.
Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010; 125(6): 490-493. doi: 10.1016/j.thromres.2009.12.023.
Ogren M, Bergqvist D, Wåhlander K, Eriksson H, Sternby NH. Trousseau’s syndrome - What is the evidence? A population-based autopsy study. Thromb Haemost. 2006; 95(3): 541-545. doi: 10.1160/TH05-10-0694.
Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004; 22(10): 1944-1948. doi: 10.1200/JCO.2004.10.002.
Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23(10): 2130-2135. doi: 10.1200/JCO.2005.03.134.
Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2(8): 1266-1271. doi: 10.1111/j.1538-7836.2004.00871.x.
Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer. 1994; 74(1): 38-45.